Research programme: antituberculosis therapeutics - Takeda/TB Alliance
Latest Information Update: 04 Jul 2016
At a glance
- Originator Takeda
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Tuberculosis
Most Recent Events
- 21 Jun 2016 Early research in Tuberculosis in Japan (unspecified route)
- 21 Jun 2016 Takeda and TB Alliance enter into an agreement to develop compounds for Tuberculosis
- 21 Jun 2016 Takeda and TB Alliance receive grant from Global Health Innovative Technology Fund for development of anti-tuberculosis therapeutics